PubMed Health⌕ Search

Biomedical subjects

J Juszczyk

Publications and source records attributed to J Juszczyk.

At least 19 recordsLinked to original sources
PubMed1992

[Liatek HCV: the six-antigen test for confirmation of the presence of anti-HCV antibodies].

Fifty eight anti-HCV repeatable positive (the UBI HCV EIA, Microelisa test Organon Teknika) blood donors were tested using LIATEK-HCV EIA (Organon Teknika). The test was constructed using synthetic polypeptides renders possible to conduct separate investigation antibodies against structural and nonstructural antigens of HCV. In 51/58 (88 per cent) cases was agreement of the results with the UBI test, in 3/58 (5.1 per cent) results were negative, and in 4/58 (6.9 per cent) undetermined. In 90 per cent of the seropositive reactivity developed with four to six antigens. The most frequent "serological pattern" was anti: NS4, C1, C2, C3, C4 (31 per cent) and anti: NS4, NS5, C1, C2, C3, C4 (23.5 per cent).

Adult↗
PubMed1992

[Anti-HCV antibodies against the structural and nonstructural antigens of hepatitis C in people seropositive in the second generation test].

Forty six anti-HCV repeatable positive (the 2nd generation Abbott EIA test) adults, among which 26 were blood donors and 19 were patients with chronic hepatitis, were tested using Abbott HCV EIA Supplemental Assay. The test renders possible to conduct separate investigation antibodies against structural and nonstructural antigens of HCV. In 44/45 (97.8 per cent) cases was an agreement of the results with the 2nd generation test. In the most of cases (80 per cent) both types of antibodies were present. However, in 20 per cent of blood donors the antibodies against structural HCV antigen were not present whereas all the chronic hepatitis patients had these type of antibodies.

Adult↗
PubMed1992

[Treatment of chronic hepatitis B with interferon alpha (Wellferon) with and without previous corticosteroid therapy -- results of a multicenter, double blind study].

The present study was aimed to test the efficacy and safety of interferon alpha (Wellferon-Wellcome Foundation Ltd.) either alone, or in combination with short-term corticosteroid pretreatment in the therapy of chronic hepatitis B. 44 patients with documented chronic hepatitis type B (12 women and 32 men; mean age 37.5 years, range 23-59 years) and satisfying the entry criteria were subjects of the study. 30 patients had chronic active hepatitis on liver biopsy, while 14 had chronic persistent hepatitis. Consecutive patients were given either placebo or prednisone in a double-blinded manner for 4 weeks (0.6 mg/kg/day in the first two weeks, 0.45 mg/kg/day in the third week and 0.25 mg/kg/day in the last week), and then, after a 2 week pause, therapy with interferon was instituted for a total of 12 weeks. Interferon was given by intramuscular injection in a single daily dose of 10 x 10(6) IU for 5 days and three times weekly thereafter. However, because of side effects, the dose of interferon was occasionally reduced to 5 x 10(6) IU in most patients. Interferon induced a sustained cessation of HBV replication as judged by loss of DNA-polymerase activity in 26 (59%) patients, 20 (45%) patients seroconverted to anti-HBe. Additionally, 6 (14%) cases lost HBsAg and seroconverted to anti-HBs. Prednisone pretreatment did not seem to improve the efficacy of interferon therapy. The outcome of the treatment was unrelated to gender and pretreatment activity of transaminases, however, patients with low activity of HBV replication were more likely to respond to therapy than patients with high HBV replication.

Adult↗
PubMed1992

[The comparison of dynamics in humoral responses in health personnel after vaccination against hepatitis B using Engerix B and Gen-H-B-vax].

The dynamics of humoral response in two groups of health care workers vaccinated according to the schedule 0, 1, 6 months, using two different recombinant vaccines has been comprised. In the group of persons vaccinated with Engerix B, 63 completed the full cycle of vaccination. Protective titer of anti-HBs (> or = 10 IU/L) was obtained in 93.6% of vaccinated. In the group of persons vaccinated with Gen-H-B-Vax, 62 completed the full cycle of vaccination, and protective titer of anti-HBs amounted to 90.3% of vaccinated. The humoral response on the protective level in both groups was not statistically different. However, the percentage of the persons with very high anti-HBs titers (10,000 and more IU/L) was higher after Engerix B.

Adolescent↗
PubMed1992

[Long term results of vaccination against viral hepatitis B using recombinant vaccine Engerix B].

Among nineteen persons vaccinated against hepatitis B (recombinant Engerix B vaccine) fifteen (80 per cent) have developed anti-HBs (investigated 30 days after the third doses) on the protective level (10 U/l). After three and a half year three of them lost antibodies, and four had anti-HBs at level below 100 U/l. All of them received a booster doses, which resulted in a very high anti-HBs level one month later. Four persons without anti-HBs after the basic vaccination received in turn two booster doses: at the 3rd and 46th month. Only one person of them have remained a non-responder. We suggest to control a level of anti-HBs one month after basic vaccination for individual determination of the term of booster dose.

Adult↗
PubMed1991

[Humoral response in health service personnel after administration of hepatitis B vaccine Gen-H-B-Vax].

Within the group of 260 members of medical staff, the presence of the HBV markers was found in 87 persons (33.5%). Vaccination, which was of a voluntary character, was initiated in the group of 75 persons according to the pattern of 0, 1, 6 months with the use of vaccine GenH-B-Vax (Merck Sharp Dohme-Chibret A. G.) was completed in 62 persons. Humoral response was investigated with quantitative measurement of anti-HBs 30 days after each doses of the vaccine. After three doses of vaccine a protective level of anti-HBs (greater than or equal to 10 IU/l) have been obtained in 90.3% of vaccinated. Humoral response was higher in the group of younger (below 35 years of life) employees. Investigated vaccine was highly immunogenic and was well tolerated.

Adolescent↗
PubMed1990

[Use of the "Multitest-CMI" in the evaluation of cutaneous delayed hypersensitivity reaction to antigens in patients with chronic diseases of the liver].

Delayed cutaneous hypersensitivity was assessed in 120 patients (among them 109 HBsAg positive), with chronic persistent hepatitis, chronic active hepatitis, and compensated as well as decompensated liver cirrhosis by simultaneous application of seven standardized antigens and negative control ("Multitest CMI"). In 21 patients, after 12-24 months the tests were repeated. The sum of indurations of all positive responses ("score") were calculated. Responsiveness measured as results below a normal values was related to the advancing of liver disease (from 13% in chronic persistent hepatitis up to 77% in compensated and 61% in decompensated liver cirrhosis). A comparative analysis (t-Student test) of the arithmetical means of the "scores" revealed statistically significant differences between results obtained in diagnostic groups. It was also dependent from the severity of liver disease. Patients with chronic persistent hepatitis (without specific treatment) and patients with chronic active hepatitis (treated using thymus extract, TFX - "Polfa") has showed an increased "score" values. In contrast to this group, all persons with liver cirrhosis without skin-responsiveness in the first and second tests (anergy) died at the period of 18 months. "Multitest CMI" can be of value in assessing of results of immunotherapy, as well as prognosis of the course of advanced liver disease.

Adult↗